Navigation Links
Rib-X Pharmaceuticals to Present at the 49th ICAAC
Date:9/10/2009

3 Sept. 15 9:00am- PK/PD Clinical Trial Dose Hall D 11:00am Investigational Selection for Poster #15 Antibacterials Delafloxacin (DFX) for Present- Complicated Skin and ation Skin-Structure #A1-1942 Infections (cSSSI) Sept. 15 9:00am- New Macrolides Enhanced Macrolides: Hall D 11:00am and Ketolides Optimized Molecular Poster #125 Properties for Oral Present- Exposure ation #F1-2049 Sept. 15 9:00am- New Macrolides Enhanced Macrolides: Hall D 10:00am and Ketolides Overcoming Resistance Poster #126 by Improving Target Present- Affinity ation #F1-2050 Sept. 15 9:00am- PK/PD Pharmacokinetics and Hall D 11:00am Investigational Pharmacodynamics of Poster #14 Antibacterials Delafloxacin in S. Present- aureus Murine Thigh ation Infection Models #A1-1941

"It is very satisfying to present for critical review the scientific developments Rib-X has fostered during the past year and in four distinctive antibiotic programs. It is especially rewarding to receive input from our peers at the premier anti-infective conference," said Susan Froshauer, PhD, President and Chief Executive Officer, Rib-X Pharmaceuticals. "We are particularly pleased to present proof-of-conc
'/>"/>

SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Rib-X Pharmaceuticals Antibiotic Drug Discovery Platform Discovers Novel Compounds with Activity Against Key Multiple Drug Resistant Gram-negative Bacteria
2. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia
3. Rib-X Pharmaceuticals, Inc. Appoints Dr. Russell Greig to Board of Directors
4. Rib-X Pharmaceuticals Announces Presentations at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
5. Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing
6. Rib-X Pharmaceuticals to Present at the 2008 ICAAC/IDSA Joint Meeting
7. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
8. Rib-X Pharmaceuticals to Present at Cambridge Healthtech Institutes 2nd Annual Challenge of Antibacterial Development Conference
9. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
10. Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of September 2009
11. Dont Wait to Innovate: Future Pharmaceuticals Magazine Releases Its Issue on Innovation in IT, Cell-Based Therapy and Supply Chains
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... According to the 2014 Liberty Mutual ... was ranked first among the leading causes of ... pushing, pulling, holding, carrying, or throwing and cost ... Round Company takes statistics like this very seriously. ... develop and design equipment that prevents these injuries ...
(Date:4/16/2015)... , April 16, 2015 /PRNewswire/ - Portage Biotech ... Canadian Securities Exchange: PBT.U), is pleased to announce that ... Show on April 25, 2015 to be held in ... Gregory Bailey and Mr. James Mellon ... and an update on the key programs at its ...
(Date:4/16/2015)... A new infographic compiles useful information ... institutions to learn how Appleā€™s new framework can change ... is ideal since Apple made Research Kit ... open-source framework for developing medical research apps that Apple ... researchers to collect secure clinical data and communicate via ...
(Date:4/16/2015)... , April 16, 2015  EMD Serono today ... Darmstadt, Germany , appointed ... Head of Global Clinical Development.  Dr. Reicin brings ... experience in Oncology and Immunology. She is an ... served as a Vice President in various capacities ...
Breaking Biology Technology:The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2Portage to Present at Master Investor 2015 in London, UK 2Portage to Present at Master Investor 2015 in London, UK 3Portage to Present at Master Investor 2015 in London, UK 4Infographic Illustrates Potential for Research Kit to Impact Clinical Research 2Infographic Illustrates Potential for Research Kit to Impact Clinical Research 3Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 3
... , ... Group,("Simcere" or the "Company") (NYSE: SCR ), ... marketing of branded,generic and proprietary pharmaceuticals in China, today ... China,s National Drug Reimbursement List,("NDRL"), which was issued by ...
... The ... camera fourth among the publication’s “Top 10 Innovations of 2009. , ... (PRWEB) December 2, 2009 -- The ... of high-performance CCD and EMCCD cameras for the life sciences, was ranked fourth among ...
... 1 PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) ... 31, 2009 of approximately $57 million, as compared with $69 ... quarter 2008 results was the first of two installment payments ... quarter 2008 results was a one-time $1.8 million payment from ...
Cached Biology Technology:Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 3The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009 2The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009 3PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3
(Date:3/24/2015)... BEACH GARDENS, Fla. , March 24, 2015 ... biometric identity management solutions, today announced that its ... premium clothing accessory retailer Goorin Bros . ... The Crossmatch biometrics-based solution secures access to the ... from the increased risk of data breaches. ...
(Date:3/23/2015)... Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, announces its biometric payment technology, ... on CNBC television starting March 30 th . ... in New York markets. ... are excited about our new ad campaign following the recent ...
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Iris Biometrics - Global Strategic Business Report" report ... markets for Iris Biometrics in US$ Thousands. The report provides ... , Japan , Europe ... , and Latin America . ...
Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... for manipulating macromolecules has been developed by researchers at ... double-stranded DNA to direct the behavior of other molecules. ... been used as a static lattice to construct geometrical ... into such shapes, the researchers are using DNA to ...
... bacterium that can cause respiratory tract infections, which can ... It is therefore important to develop a vaccine against ... advance of print publication of the May issue of ... from Cornell University use a novel strategy to create ...
... Investigators from the University California, San Diego (UCSD) Branch ... NimbleGen Systems have developed an efficient method to identify ... to a study published today in Nature. , Genes ... product. Thus the 'promoter' - a DNA sequence that ...
Cached Biology News:DNA constraints control structure of attached macromolecules 2Whole genome promoter mapping - Human Genome Project v2.0? 2
BD BioCoat Collagen IV 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse collagen type IV....
... designed for sequencing inserts cloned into M13/pUC-based ... T3 RNA polymerase promoters, or lambda gt10 ... a concentration of 0.1 µg/µl in water. ... sequencing reactions using SequiTherm™ EXCEL™ II DNA ...
BD BioCoat Collagen I 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of rat tail collagen type I....
Topoisomerase II...
Biology Products: